HOCPY:OTC-Hoya Corp (USD)

COMMON STOCK | Medical Instruments & Supplies |

Last Closing

USD 114.62

Change

+1.36 (+1.20)%

Market Cap

USD 36.78B

Volume

0.03M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

HOYA Corporation, a med-tech company, provides high-tech and medical products worldwide. It operates through three segments: Life Care, Telecommunication, and Other. The company offers life care products, including eyeglass and contact lenses; medical endoscopes; intraocular lenses; laparoscopic surgical instruments; automatic endoscope cleaning equipment; and other medical related products, such as prosthetic ceramic fillers and metallic implants for orthopedics. It also operates Eyecity, a specialty retailer of contact lenses. In addition, the company provides information technology products, such as mask blanks and photomasks for manufacturing semiconductor chips; glass disks for hard disk drives; and imaging products that include optical glasses/optical lenses, colored glass filters, and laser equipment/UV light resources. Further, it engages in the research, development, manufacture, and sale of photomasks for manufacturing flat panel displays. Additionally, the company offers ReadSpeaker, a speech synthesis software; and cloud services comprising Kinnosuke, a time and attendance management service, as well as Yonosuke, an electronic payslip service. HOYA Corporation was founded in 1941 and is headquartered in Tokyo, Japan.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-24 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap
ESLOF EssilorLuxottica Société ano..

-0.05 (-0.02%)

USD 128.93B
ESLOY Essilor International SA

-1.33 (-0.91%)

USD 123.63B
HOCPF HOYA Corporation

+9.72 (+9.19%)

USD 36.78B
CLPBY Coloplast A

+0.12 (+1.11%)

USD 30.06B
TRUMF Terumo Corporation

-1.72 (-8.77%)

USD 27.92B
CLPBF Coloplast A/S

N/A

USD 23.07B
SRTOY Sartorius Stedim Biotech S.A

+0.14 (+0.58%)

USD 21.84B
SDMHF Sartorius Stedim Biotech S.A

N/A

USD 19.85B
SAUHF Straumann Holding AG

+0.36 (+0.30%)

USD 17.44B
SOAGY Sartorius Aktiengesellschaft

+0.16 (+0.30%)

USD 15.21B

ETFs Containing HOCPY

1642:TSE 4.79 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Instruments & Supplies) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -7.56% 39% F 38% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -7.56% 38% F 37% F
Trailing 12 Months  
Capital Gain -2.44% 59% D- 54% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -2.44% 58% F 51% F
Trailing 5 Years  
Capital Gain 24.18% 80% B- 62% D
Dividend Return 3.08% 9% A- 5% F
Total Return 27.26% 78% C+ 57% F
Average Annual (5 Year Horizon)  
Capital Gain 2.27% 54% F 45% F
Dividend Return 2.27% 52% F 41% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 28.01% 79% B- 74% C
Risk Adjusted Return 8.12% 57% F 44% F
Market Capitalization 36.78B 94% A 97% N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector